drugset
drugset / Trial / NCT02043379

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379 ↗

Completed 50 enrolled University of Alabama at Birmingham Grifols Biologicals, LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study protocol is to determine if administering Intravenous Immunoglobulin (IVIG) for treatment of cardiopulmonary bypass (CPB) induced hypogammaglobulinemia in the early post-operative period can impact post-surgical outcomes (i.e., infection, fluid overload, and associated morbidities).

Timeline

Start
2014-05
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 1 g/kg Intravenous

Indications

congenital heart disease immunodeficiency disease